Trials / Completed
CompletedNCT04630444
Riluzole Effects on Hippocampus Biomarkers
An Investigational Study of Riluzole Effects on Hippocampus Biomarkers
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Mclean Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To examine the clinical efficacy of the anti-glutamatergic medication riluzole in posttraumatic stress disorder (PTSD), and its effect on hippocampus biomarkers that our laboratory previously has identified using MRS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Riluzole | 30 PTSD patients with riluzole 100 mg daily (50 mg bid). |
Timeline
- Start date
- 2017-03-16
- Primary completion
- 2019-03-16
- Completion
- 2019-03-16
- First posted
- 2020-11-16
- Last updated
- 2020-11-16
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04630444. Inclusion in this directory is not an endorsement.